Levodopa-carbidopa intestinal gel vs TR-012001
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Parkinson's Disease
Shared mechanism: dopamine precursor · full Parkinson's Disease pipeline
Levodopa-carbidopa intestinal gel · Duopa
Marketed by AbbVie
NCT00335153 · Phase 3 · completed
This was a 354-participant, open-label, single-group study with no randomization, blinding, or comparator arm. Its primary outcomes focused on safety and device complications, and there was no formal controlled primary efficacy comparison, so the reported secondary improvements do not establish treatment efficacy.
Reported efficacy
Change From Baseline to Week 12 in Average Daily Normalized "Off" Time (Baseline, Week 12): Change From Baseline to Week 12 in Average Daily Normalized "Off" Time (Baseline, Week 12): LCIG + Placebo Capsules -4.04 hours (Standard Error 0.65) vs Placebo Gel + Levodopa-Carbidopa Capsules -2.14 hours (Standard Error 0.66) (met)
Result source: NCT00357994
TR-012001
Developed by SNLD, Ltd.
NCT06212089 · Phase 2 · completed
The study randomly assigned 12 Japanese patients with Parkinson's disease to one nasal dose of TR-012001 or placebo, single-blind. Its registered primary outcomes were safety measures, so there is no efficacy comparison to call. The AAN 2025 abstract reports that all adverse drug reactions were mild, transient nasal reactions and that 8 of 9 treated patients reached peak plasma levodopa within 15 minutes. The study is very small and tested a single dose.
Conference abstract (AAN 2025); not peer reviewed and not posted on ClinicalTrials.gov.
Reported efficacy
Safety evaluation of TR-012001: Incidents of Treatment-Emergent Adverse Events (Day of administration of TR-012001/placebo (Day3) to the day of leaving the facility (Day4). If any adverse event(s) continue or occur on Day4, follow-up will be conducted until recovery or until the investigator decides no longer follow-up is necessary.); Safety evaluation of TR-012001: Incidents of physical findings (4 days and 3 nights); Safety evaluation of TR-012001: Vital sign (body temperature) (4 days and 3 nights); Safety evaluation of TR-012001: Vital sign (blood pressure) (4 days and 3 nights); Safety evaluation of TR-012001: Vital sign (pulse rate) (4 days and 3 nights); Safety evaluation of TR-012001: Columbia Suicide Severity Rating Scale (C-SSRS) (Day 1 and Day 4); Safety evaluation of TR-012001: Incidents of participants with laboratory abnormality (Day 1 and Day 4); Pharmacokinetics of TR-012001: Maximum plasma concentration (Cmax) (Pre-dose (baseline) and specified time points of post-dose); Pharmacokinetics of TR-012001: Time to reach maximum plasma concentration (Tmax) (Pre-dose (baseline) and specified time points of post-dose); Pharmacokinetics of TR-012001: Elimination half-life (t1/2) (Pre-dose (baseline) and specified time points of post-dose); Pharmacokinetics of TR-012001: Area under the plasma concentration-time curve (AUC0-inf) (Pre-dose (baseline) and specified time points of post-dose); Pharmacokinetics of TR-012001: Mean residence time (MRT) (Pre-dose (baseline) and specified time points of post-dose); Pharmacokinetics of TR-012001: Apparent whole body clearance (CL/f) (Pre-dose (baseline) and specified time points of post-dose); Pharmacokinetics of TR-012001: Volume of distribution (Vd/f ) (Pre-dose (baseline) and specified time points of post-dose): Single nasal dose in 12 patients (9 TR-012001, total levodopa 40 mg; 3 placebo): all adverse drug reactions were mild and transient nasal administration reactions, and all 12 patients completed. 8 of 9 TR-012001 patients reached peak plasma levodopa within 15 minutes of dosing. (not_applicable)
Result source: NCT06212089
Results for Parkinson's Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Levodopa-carbidopa intestinal gel | TR-012001 |
|---|---|---|
| OFF time, change | -4.0 vs -2.1vs Levodopa-Carbidopa CapsulesNCT003579942 other results
| —Not reported |
| ON time without troublesome dyskinesia, change | 4.1 vs 2.2vs Levodopa-Carbidopa CapsulesNCT003579941 other result
| —Not reported |
| UPDRS Part III, change | -1.5 vs -2.9vs Levodopa-Carbidopa CapsulesNCT003579942 other results
| —Not reported |
| MDS-UPDRS Part II, change | —Not posted · NCT01960842 | —Not reported |
OFF time, change
- Levodopa-carbidopa intestinal gel
- -4.0 vs -2.1vs Levodopa-Carbidopa CapsulesNCT00357994
2 other results
- -4.0 vs -2.1 NCT00660387
- -2.2 vs 0.2 NCT02799381
- TR-012001
- —Not reported
ON time without troublesome dyskinesia, change
- Levodopa-carbidopa intestinal gel
- 4.1 vs 2.2vs Levodopa-Carbidopa CapsulesNCT00357994
1 other result
- 3.1 vs -0.1 NCT02799381
- TR-012001
- —Not reported
UPDRS Part III, change
- Levodopa-carbidopa intestinal gel
- -1.5 vs -2.9vs Levodopa-Carbidopa CapsulesNCT00357994
2 other results
- -4.9 vs -0.9 NCT02799381
- -1.5 vs -2.9 NCT00660387
- TR-012001
- —Not reported
MDS-UPDRS Part II, change
- Levodopa-carbidopa intestinal gel
- —Not posted · NCT01960842
- TR-012001
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
TR-012001: no structured comparison results are available for Parkinson's Disease.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Levodopa-carbidopa intestinal gel: 4 of 4 rows · TR-012001: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Levodopa-carbidopa intestinal gel |
|---|---|
| Dropout rate | 8.5%a NCT00335153 · Phase 3 show 13 more results5.4% NCT00357994 · Phase 3 43.2%Duodopa Naïve NCT00141518 · Phase 4 · registry result, not featured evidence 27.3%Duodopa Non-naïve < 2 Years NCT00141518 · Phase 4 · registry result, not featured evidence 33.3%Duodopa Non-naïve ≥ 2 Years NCT00141518 · Phase 4 · registry result, not featured evidence 15.6% NCT02549092 · Phase 3 · registry result, not featured evidence 44.7% NCT00660673 · Phase 3 · registry result, not featured evidence 10.7% NCT02799381 · Phase 3 · registry result, not featured evidence — NCT01736176 · Phase 3 · registry result, not featured evidence 9.7% NCT01960842 · Phase 3 · registry result, not featured evidence — NCT00360568 · Phase 3 · registry result, not featured evidence 5.4% NCT00660387 · Phase 3 · registry result, not featured evidence 37.5% NCT01479127 · Phase 2 · registry result, not featured evidence — NCT02448914 · Phase 1 · registry result, not featured evidence · Parkinson's Disease · phase 1 |
| Discontinued due to AEs | 1.4%a NCT00335153 · Phase 3 show 13 more results2.7% NCT00357994 · Phase 3 18.9%Duodopa Naïve NCT00141518 · Phase 4 · registry result, not featured evidence 22.7%Duodopa Non-naïve < 2 Years NCT00141518 · Phase 4 · registry result, not featured evidence 11.1%Duodopa Non-naïve ≥ 2 Years NCT00141518 · Phase 4 · registry result, not featured evidence 4.4% NCT02549092 · Phase 3 · registry result, not featured evidence 32.1% NCT00660673 · Phase 3 · registry result, not featured evidence 3.6% NCT02799381 · Phase 3 · registry result, not featured evidence — NCT01736176 · Phase 3 · registry result, not featured evidence 3.2% NCT01960842 · Phase 3 · registry result, not featured evidence — NCT00360568 · Phase 3 · registry result, not featured evidence 2.7% NCT00660387 · Phase 3 · registry result, not featured evidence — NCT01479127 · Phase 2 · registry result, not featured evidence — NCT02448914 · Phase 1 · registry result, not featured evidence · Parkinson's Disease · phase 1 |
| Serious AEs | 30.5%a NCT00335153 · Phase 3 show 13 more results13.5% NCT00357994 · Phase 3 66.7%Duodopa Naïve NCT00141518 · Phase 4 · registry result, not featured evidence 77.3%Duodopa Non-naïve < 2 Years NCT00141518 · Phase 4 · registry result, not featured evidence 77.8%Duodopa Non-naïve ≥ 2 Years NCT00141518 · Phase 4 · registry result, not featured evidence 20.9% NCT02549092 · Phase 3 · registry result, not featured evidence 60.7% NCT00660673 · Phase 3 · registry result, not featured evidence 7.1% NCT02799381 · Phase 3 · registry result, not featured evidence 20.5% NCT01736176 · Phase 3 · registry result, not featured evidence 12.9% NCT01960842 · Phase 3 · registry result, not featured evidence 22.6% NCT00360568 · Phase 3 · registry result, not featured evidence 13.5% NCT00660387 · Phase 3 · registry result, not featured evidence 16.7% NCT01479127 · Phase 2 · registry result, not featured evidence 0% NCT02448914 · Phase 1 · registry result, not featured evidence · Parkinson's Disease · phase 1 |
| Most frequent reported AEs | show 13 more resultsconstipation 22.2% depression 19.4% device dislocation 19.4% NCT00141518 · Phase 4 · registry result, not featured evidence device dislocation 36.4% excessive granulation tissue 31.8% device related infection 27.3% NCT00141518 · Phase 4 · registry result, not featured evidence blood homocysteine increased 33.3% device dislocation 27.8% constipation 22.2% NCT00141518 · Phase 4 · registry result, not featured evidence stoma site pain 14% abdominal pain 11.6% stoma site infection 11.6% NCT02549092 · Phase 3 · registry result, not featured evidence vitamin b6 decreased 27.1% blood homocysteine increased 22.5% postoperative wound infection 21% NCT00660673 · Phase 3 · registry result, not featured evidence fall 21.4% procedural pain 10.7% abdominal pain 7.1% NCT02799381 · Phase 3 · registry result, not featured evidence procedural pain 33.3% stoma site infection 28.2% stoma site pain 23.1% NCT01736176 · Phase 3 · registry result, not featured evidence incision site pain 41.9% excessive granulation tissue 32.3% constipation 19.4% NCT01960842 · Phase 3 · registry result, not featured evidence incision site erythema 29% fall 21% vitamin b6 decreased 21% NCT00360568 · Phase 3 · registry result, not featured evidence complication of device insertion 54.1% abdominal pain 51.4% nausea 29.7% NCT00660387 · Phase 3 · registry result, not featured evidence dyskinesia 33.3% fall 33.3% anaemia 16.7% NCT01479127 · Phase 2 · registry result, not featured evidence cold sweat 9.1% diarrhoea 9.1% headache 9.1% NCT02448914 · Phase 1 · registry result, not featured evidence · Parkinson's Disease · phase 1 |
Notes
- aPopulation comparability has not been reviewed for 13 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Levodopa-carbidopa intestinal gel
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
+ 333 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Levodopa-carbidopa intestinal gel's landscape · TR-012001's landscape